RESUMEN
Ensuring uniform illuminance in waveguide-based augmented reality (AR) display devices is crucial for providing an immersive and comfortable visual experience. However, there is a lack of a straightforward and efficient design method available to achieve illuminance uniformity over the full field of view. To address this issue, we propose a novel design that utilizes random mask gratings (RMGs) as the folding grating and the out-coupling grating. Unlike traditional approaches that modify the grating structure, we control the diffraction efficiency distribution by adjusting the filling factor of the mask while keeping the grating structure unchanged in one RMG. The grating structures are designed and optimized based on rigorous coupled wave analysis and particle swarm optimization. The feasibility of our method is verified by the simulation results in Lighttools. In the FOV range of 20°×15°, the eyebox uniformities of all fields are greater than 0.78, which can provide a good visual experience for users.
RESUMEN
Background: There is insufficient evidence to assess the risk of the production of clinically important alloimmune irregular red blood cell (RBC) antibodies in first-time pregnant women. Methods: Using the microcolumn gel antiglobulin method, 18,010 Chinese women with a history of pregnancy and pregnant women were screened for irregular RBC antibodies, and for those with positive test results, antibody specificity was determined. The detection rate and specificity of irregular RBC antibodies in women with a history of multiple pregnancies (two or more) and first-time pregnant women were determined. Results: In addition to 25 patients who passively acquired anti-D antibodies via an intravenous anti-D immunoglobulin injection, irregular RBC antibodies were detected in 121 (0.67%) of the 18,010 women. Irregular RBC antibodies were detected in 93 (0.71%) of the 13,027 women with a history of multiple pregnancies, and antibody specificity was distributed mainly in the Rh, MNSs, Lewis, and Kidd blood group systems; irregular RBC antibodies were detected in 28 (0.56%) of the 4983 first-time pregnant women, and the antibody specificity was distributed mainly in the MNSs, Rh, and Lewis blood group systems. The difference in the percentage of patients with irregular RBC antibodies between the two groups was insignificant (χ 2 = 1.248, P > 0.05). Of the 121 women with irregular RBC antibodies, nine had anti-Mur antibodies, and one had anti-Dia antibodies; these antibodies are clinically important but easily missed because the antigenic profile of the reagent RBCs that are commonly used in antibody screens does not include the antigens that are recognized by these antibodies. Conclusion: Irregular RBC antibody detection is clinically important for both pregnant women with a history of multiple pregnancies and first-time pregnant women. Mur and Dia should be included in the antigenic profile of reagent RBCs that are used for performing antibody screens in the Chinese population.
Asunto(s)
Eritrocitos , Humanos , Femenino , Embarazo , Eritrocitos/inmunología , China , Adulto , Embarazo Múltiple , Isoanticuerpos/sangre , Globulina Inmune rho(D)/sangre , Sensibilidad y Especificidad , Especificidad de Anticuerpos , Sistema del Grupo Sanguíneo MNSs/inmunología , Pueblo Asiatico , Sistema del Grupo Sanguíneo de Kidd/inmunología , Pueblos del Este de AsiaRESUMEN
Various substances in the blood plasma serve as prognostic indicators of the progression of COVID-19. Consequently, multi-omics studies, such as proteomic and metabolomics, are ongoing to identify accurate biomarkers. Cytokines and chemokines, which are crucial components of immune and inflammatory responses, play pivotal roles in the transition from mild to severe illness. To determine the relationship between plasma cytokines and the progression of COVID-19, we used four study cohorts to perform a systematic study of cytokine levels in patients with different disease stages. We observed differential cytokine expression between patients with persistent-mild disease and patients with mild-to-severe transformation. For instance, IL-4 and IL-17 levels significantly increased in patients with mild-to-severe transformation, indicating differences within the mild disease group. Subsequently, we analysed the changes in cytokine and chemokine expression in the plasma of patients undergoing two opposing processes: the transition from mild to severe illness and the transition from severe to mild illness. We identified several factors, such as reduced expression of IL-16 and IL-18 during the severe phase of the disease and up-regulated expression of IL-10, IP-10, and SCGF-ß during the same period, indicative of the deterioration or improvement of patients' conditions. These factors obtained from fine-tuned research cohorts could provide auxiliary indications for changes in the condition of COVID-19 patients.